The US Supreme Court has ruled in Louisiana v. FDA to continue allowing telehealth, mailing and pharmacy provision of mifepristone—the first drug in the most common medication abortion regimen in the United States. Kelly Baden, Guttmacher's vice president for public policy, explains that while this decision is a relief, we are not celebrating. The case will continue in lower courts where the anti-abortion movement will push their relentless campaign against medication abortion. The science has not changed: mifepristone is safe and effective.
Kelly Baden on the LA v. FDA SCOTUS decision
Video
Transcript: The US Supreme Court has ruled to allow telehealth mailing and pharmacy provision of mifepristone to continue nationwide. This decision provides urgently needed relief after weeks of disruption to abortion access. But we're not fully celebrating yet. This case will continue in lower courts, and access to abortion care remains fragile despite the fact that the science hasn't changed.
Mifepristone is safe and effective, whether it is provided in person or via telehealth. The whiplash of the past several weeks on top of the reverberations of overturning Roe v. Wade in 2022 has already caused real disruptions and continues to put patients and providers at the mercy of judges. The fight to protect medication abortion is not over, and mifepristone access via telehealth remains under attack.
Patients, providers, and communities have endured relentless attacks on abortion, and it is long past time for courts and policymakers to follow the science and protect mifepristone from ideological threats. To access abortion care, head to plancpills.com or ineedana.com.